Recent news around Tempus AI (TEM) has centered on its GenoPredicta collaboration with Predicta Biosciences and fresh AACR 2026 data, spotlighting cancer diagnostics capabilities that some investors ...
Tempus AI Inc TEM shares are trading higher Wednesday after the company announced a collaboration with Predicta Biosciences ...
Brian McKernan joins as CEO to further advance Predicta’s clinical impact, including its non-invasive diagnostic for Multiple Myeloma “It’s an honor to join Predicta and our strong team of leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results